| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/31/2006 | US6992105 N-[2-[(S)-2-Acetylthio-3-methylbutanoylamino]-2-methylpropionyl]-O-ben-zyl-L-serine Ethyl; inhibitors of angiotensin converting enzyme, neutral endopeptidase, endothelin converting enzyme. |
| 01/31/2006 | US6992104 C7 carbonate taxane compositions |
| 01/31/2006 | US6992103 amidation and/or dehalogenation to form substituted [4-carbamoyl-2-hydroxypentyl]-benzamides; potent enzyme inhibitors of Asp2 [B-secretase, BACE1 (b-site Alzheimer's amyloid precursor protein cleaving enzyme) or Memapsin]; Alzheimer's disease |
| 01/31/2006 | US6992102 Bicyclic modulators of androgen receptor function |
| 01/31/2006 | US6992101 indole and thieno (2,3-B)pyrrole compounds with 1,1-dioxo tetrahydro thiophene or pyran ring; treating diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, hypertension, hyperinsulinemia, hyperlipidemia, ischemia |
| 01/31/2006 | US6992100 sPLA2 inhibitors |
| 01/31/2006 | US6992099 For controlling parasites in or on an animal |
| 01/31/2006 | US6992098 A fluorinated compounds, microbiocides, synthesis with chemical intermediates, amidation, debromination, benzylation, oximination |
| 01/31/2006 | US6992097 such as methyl-1-{2-[4-((2R)-2-{2-[(tert-butoxy)carbonylamino]-2-methylpropanoylamino}-3-indol-3-ylpropanoylamino)imidazolyl]-2-phenylacetyl}pyrrolidine-2-carboxylate |
| 01/31/2006 | US6992096 translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid |
| 01/31/2006 | US6992095 Stilbene compounds comprising an adamantyl group, compositions and methods thereof |
| 01/31/2006 | US6992094 selenium nicotinic acid tetrahyronaphthaline compounds; treating skin disorders |
| 01/31/2006 | US6992093 Method of inhibiting lipofibroblast to myofibroblast transdifferentiation |
| 01/31/2006 | US6992092 Anti-diabetic agents |
| 01/31/2006 | US6992091 Antihistamines; antiallergens; antiinflammatory agents; autoimmune diseases; antiarthritic agents |
| 01/31/2006 | US6992090 Substituted piperidine compounds and methods of their use |
| 01/31/2006 | US6992089 Anticancer agents; bactericides, fungicides |
| 01/31/2006 | US6992088 Tetracyclic or pentacyclic cytotoxic agents, enzyme inhibitors, anticarcinogenic agents, bactericides, fungicides |
| 01/31/2006 | US6992087 Substituted aryl 1,4-pyrazine derivatives |
| 01/31/2006 | US6992086 Antagonists of MCP-1 function and methods of use thereof |
| 01/31/2006 | US6992085 Octahydro-2H-pyrido[1,2-a]pyrazine compounds |
| 01/31/2006 | US6992084 Compounds and methods for modulating CXCR3 function |
| 01/31/2006 | US6992083 Benzoxazol derivatives |
| 01/31/2006 | US6992082 for treatment of cellular proliferative diseases such as cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation |
| 01/31/2006 | US6992081 Such as 4-((6-(3,5-difluoro-phenyl)-5-(S)-(3-dipropylcarb-amoyl-benzoyl-amino)-2-(R)-ethyl-4-(S)-hydroxy-hexanoylamino)-methyl)-cyclohexanecarboxylic acid for inhibiting secretase activity and cleavage of amyloid precursor protein |
| 01/31/2006 | US6992080 For therapy of cancer, inflammation, arthritis, viral diseases, neurodegenerative diseases such as Alzheimer's disease, cardiovascular diseases, and fungal diseases |
| 01/31/2006 | US6992079 Antiproliferative agent |
| 01/31/2006 | US6992078 Solvent extraction, separation, crystallization |
| 01/31/2006 | US6992077 Spirocyclic ligands for sigma receptors, and libraries and methods of use thereof |
| 01/31/2006 | US6992076 Providing sustained systemic concentrations of therapeutic or prophylactic agents such as gamma-aminobutyric acid derivatives following oral adiminstration to animals |
| 01/31/2006 | US6992075 dehydrogenating estrogenic salts by heating in high humidity to produce conjugated estrogen salts; 14-hydroxy (or hydroperoxy)- Delta 8,9-Dehydroestrone Sodium Sulfate; side effect reduction; hormone replacement therapy |
| 01/31/2006 | US6992074 2-Ethyl and 2-ethylidene-19-nor-vitamin D compounds |
| 01/31/2006 | US6992073 Use of N-acetyl-D-glucosamine in the manufacture of a medicament for treating cervical erosion |
| 01/31/2006 | US6992072 comprises pyrimidine-based nucleosides; highly active anti-retroviral therapy; treating lipoatrophy, dyslipidemia, and insulin resistance resulting from administration of nucleoside reverse transcriptase inhibitors |
| 01/31/2006 | US6992071 Methods for modulating phototoxicity |
| 01/31/2006 | US6992070 Treating tissue with phosphodiesterase inhibitor compound and administering exogenous nucleic acid |
| 01/31/2006 | US6992069 Tricyclic macrolide antibacterial compounds |
| 01/31/2006 | US6992068 Brazilian licorice extract and periandrins, which are constituents thereof, have an anti inflammatory effect and an immunosuppressive effect |
| 01/31/2006 | US6992067 Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use |
| 01/31/2006 | US6992065 Sustained release formulations |
| 01/31/2006 | US6992061 Removing endotoxin lipopolysacchardie from preparation of alpha-1-acid glycoprotein (orosomucoid) by contact with a finely divided non-toxic resin such as fumed silica |
| 01/31/2006 | US6991936 Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 01/31/2006 | US6991921 Hyaluronan synthase gene and uses thereof |
| 01/31/2006 | US6991916 Nucleotide sequences coding polypeptide for use in the treatment of sexual disorders |
| 01/31/2006 | US6991901 Administering an antibody to the polypeptide sec1; angiogenesis inhibitors |
| 01/31/2006 | US6991817 Acid-modified arabinogalactan protein composition |
| 01/31/2006 | US6991816 Aqueous solution of flavonoids and anthocyanins |
| 01/31/2006 | US6991815 compositions which are effective in preventing and/or treating peptic ulcer diseases, comprising an effective amount of American ginseng and/or its extract |
| 01/31/2006 | US6991814 Herbal medicaments for the treatment of neurocerebrovascular disorders |
| 01/31/2006 | US6991813 Physiological tissue repair and functional organ regeneration by cultivation of regenerative stem cells in vivo and in situ |
| 01/31/2006 | US6991812 Agent for preventing, improving or treating hypertension |
| 01/31/2006 | US6991807 Four different dosage forms, two antibiotics inhibiting protein and non-protein synthesis, one comprising immediate release and sustained release, the other three has sustained release forms, twenty-four hour period; bacterial infections |
| 01/31/2006 | US6991806 Pharmaceutical compositions comprising ibuprofen and domperidone |
| 01/31/2006 | US6991804 Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia |
| 01/31/2006 | US6991801 topical veterinary formulations, such as spot-on and pour-on formulations, which are used in treating, controlling and preventing of endo and ectoparasite infections in warm-blooded animals or birds, such as horses, cattle, sheep, pigs and pets |
| 01/31/2006 | US6991779 Biologically active molecules encapsulated in self-assembling, diketopiperazine microspheres, TECHNOSPHEREs tm ) and methods for making and administering such compositions are described herein. The compositions can be used to immunize individuals |
| 01/31/2006 | US6991776 Halogenated xanthene or halogenated xanthene derivative; cancer treatment |
| 01/31/2006 | US6991624 Methods and compositions for use in perfusion applications |
| 01/31/2006 | CA2433193C Amide derivative of amlodipine |
| 01/31/2006 | CA2390104C Method for transfer of molecular substances with prokaryotic nucleic acid-binding proteins |
| 01/31/2006 | CA2346447C Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection |
| 01/31/2006 | CA2327498C Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors |
| 01/31/2006 | CA2314154C Azepine or larger medium ring derivatives and their use as pharmaceuticals |
| 01/31/2006 | CA2259345C Anthranilic acid diamides derivatives, their preparation and pharmaceutical use as anti-gastrin agents |
| 01/31/2006 | CA2224635C Pyridine derivatives, process for preparing the same, and intermediate therefor |
| 01/31/2006 | CA2208839C Quinuclidine derivatives and medicinal composition thereof |
| 01/31/2006 | CA2171627C Rectally-administered, epileptic-seizure-inhibiting composition |
| 01/31/2006 | CA2158855C Water-soluble camptothecin derivatives, process for their preparation and their use as antitumor agents |
| 01/31/2006 | CA2152506C Use of prodelphinidines for treating osteoarthritis |
| 01/31/2006 | CA2150806C Antiallergic triazolobenzazepine derivatives |
| 01/31/2006 | CA2150803C Controlled release growth hormone containing microspheres |
| 01/31/2006 | CA2149924C Use of phenserine to treat cognitive disorders |
| 01/31/2006 | CA2119261C Novel sidechain-bearing taxanes and intermediates thereof |
| 01/31/2006 | CA2067365C Illudin analogs as anti-tumor agents |
| 01/30/2006 | CA2514000A1 Fexofenadine base polymorphic forms |
| 01/30/2006 | CA2513936A1 Compositions and methods for treating skin conditions |
| 01/29/2006 | CA2513997A1 Use of a chemically modified starch product |
| 01/29/2006 | CA2513913A1 Use of a crosslinked or inhibited starch product |
| 01/27/2006 | CA2475762A1 Dose dependent elimination of ha and cell receptor stimulation |
| 01/26/2006 | WO2006010162A2 COMPOSITIONS COMPRISING 5-ALPHA REDUCTASE INHIBITORS, AND SERMs AND METHODS OF USE THEREOF |
| 01/26/2006 | WO2006010153A2 Lipid-amino acid conjugates and methods of use |
| 01/26/2006 | WO2006010152A2 Formulations for parenteral administration of (e)-2,6-dialkoxystryryl 4-substituted benzylsulfones |
| 01/26/2006 | WO2006010147A2 Control of biofilm formation |
| 01/26/2006 | WO2006010146A2 Functional variant of lymphoid tyrosine phosphatase is associated with autoimmune disorders |
| 01/26/2006 | WO2006010127A2 Therapeutic compound and treatments |
| 01/26/2006 | WO2006010118A2 Conformationally constrained smac mimetics and the uses thereof |
| 01/26/2006 | WO2006010085A1 Use of neurosteroids to treat neuropathic pain |
| 01/26/2006 | WO2006010079A2 Process for preparing naratriptan hydrochloride |
| 01/26/2006 | WO2006010078A2 Polymorphic form of naratriptan hydrochloride |
| 01/26/2006 | WO2006010077A2 Prodrugs of lonidamine and lonidamine analogs |
| 01/26/2006 | WO2006010069A1 Materials and methods for immune system stimulation |
| 01/26/2006 | WO2006010041A2 Morpholino antisense drugs for human herpesvirus 8 |
| 01/26/2006 | WO2006010009A2 Hyaluronic acid in the enhancement of lens regeneration |
| 01/26/2006 | WO2006009975A2 Histamine to treat disorders affecting muscle function |
| 01/26/2006 | WO2006009893A2 Cancer chemotherapy |
| 01/26/2006 | WO2006009890A2 Methods and compositions for producing insulin sensitization |
| 01/26/2006 | WO2006009876A2 Trisubstituted nitrogen modulators of tyrosine phosphatases |
| 01/26/2006 | WO2006009874A2 Methods and compositions for treatment of excess nitric oxide or cyanide toxicity |
| 01/26/2006 | WO2006009869A1 Coumpounds and methods for inhibiting the interaction of bcl proteins with binding partners |
| 01/26/2006 | WO2006009840A1 Benzoquinone compounds as a anti-cancer agents |